Understanding how aging immune cells contribute to Alzheimer's disease
Official title: Metabolic Control of T Cell Senescence in Pathogenesis and Immunotherapy of Alzheimer's Disease
Funded at Washington University · NIH-11080924 · Data updated 2026-11-12
This study is looking at how aging immune cells called T cells might affect the buildup of harmful proteins in Alzheimer's disease, with the hope of finding new ways to help people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 1, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $380,975 |
| NIH project number | 5R01AG078822-04 |
| Project ID | NIH-11080924 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include older adults who are at risk of developing Alzheimer's disease or those already diagnosed with the condition.
✕Less likely to help
Patients with early-onset Alzheimer's disease or those with non-age-related forms of dementia may not benefit from this research.
What this research studies
This research investigates the role of aging immune cells, specifically T cells, in the development and progression of Alzheimer's disease (AD). It aims to uncover the mechanisms by which senescent T cells may influence the accumulation of harmful proteins associated with AD, such as amyloid beta and Tau. By studying these processes, the research seeks to identify potential new therapeutic strategies that could improve treatment options for patients with AD. The approach includes analyzing the metabolic activity and secretory profiles of these immune cells in both human samples and animal models.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that slow down or prevent the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in understanding the immune system's role in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Peng, Guangyong — Washington University
- Study coordinator: Peng, Guangyong
Related research
Other NIH-funded projects on the same topics.
-
Immune cell aging and metabolism as a target for Alzheimer's treatment
This work looks at whether aging immune cells called T cells and their fat-related metabolism drive Alzheimer's and whether changing them could point to new treatments for people with AD.
-
Blood–brain barrier and tiny brain changes linked to side effects and outcomes of anti‑amyloid treatment for Alzheimer’s
This project will look at blood–brain barrier health and small brain changes to help predict side effects and treatment outcomes for people with Alzheimer’s disease.
-
Investigating brain changes and risks from new Alzheimer's treatments
This study is looking at how new treatments for Alzheimer's disease might affect the brain, especially any potential risks, so we can better understand how to keep patients safe while using these therapies.
-
Investigating immune interactions in Alzheimer's disease and testing a new immunotherapy
This study is looking at how inflammation might impact Alzheimer's disease by checking certain markers in your blood and spinal fluid, and it will also test a new low-dose treatment to see if it helps improve brain function and memory over 22 weeks for people with Alzheimer's.
-
New treatment targeting tau protein for Alzheimer's disease
This study is working on a new treatment for Alzheimer's disease that uses special antibodies to target a harmful protein in the brain, with the hope of helping people with Alzheimer's feel better and protect their brain health.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.